EXCLUSIVE: US House committee opens investigation into Merck, AbbVie China drug trials - Reuters
EXCLUSIVE: US House committee opens investigation into Merck, AbbVie China drug trials Reuters
The investigation likely stems from ongoing geopolitical tensions and increased scrutiny of foreign influence in critical sectors, particularly healthcare and pharmaceuticals, following heightened US-China competition.
A US House investigation into major pharmaceutical companies conducting drug trials in China signifies growing regulatory and geopolitical risk for multinational corporations operating across these two economic blocs.
This event intensifies pressure on pharmaceutical companies to review and potentially reconfigure their global research and development strategies, particularly regarding data security, intellectual property, and geopolitical alignment.
- · US domestic pharmaceutical R&D
- · Onshore clinical trial services
- · US regulatory oversight agencies
- · Merck
- · AbbVie
- · Pharmaceutical companies with extensive China R&D
- · China's pharmaceutical clinical trial sector
Increased scrutiny and potential sanctions on pharmaceutical companies with significant R&D operations in China.
Pharmaceutical companies may accelerate the diversification of their clinical trial locations away from China, impacting drug development timelines and costs.
This could lead to a broader 'decoupling' of medical and scientific research between the US and China, fragmenting global scientific collaboration.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at Reuters — Technology (Google News)